Kovina Therapeutics Inc.
Indianapolis, IN · Founded 2020 · CIK 0001872402 · Biotech · Private
Small molecule inhibitors of HPV-16 E6 protein that block E6-mediated p53 degradation
kovina.com →- Grants
- $2.9M
- 5 awards
- Sector median: 1
- Raised
- $2.0M
- 1 Form D · Jul 2021
- 63 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 5 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer | $420,989 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule E6 Inhibitors to Treat Dysplasia Caused by HPV Infections | $298,527 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule E6 Inhibitors to Treat Oropharyngeal Cancers Caused by HPV Infections | $275,766 | |
| Federal grant | Department of Health and Human Services · Phase II · From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer | $909,657 | |
| Federal grant | Department of Health and Human Services · Phase II · From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer | $1,000,028 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2551 | BACTRIA PHARMACEUTICALS LLC | — | — |
| 2552 | Regenimo Biosciences, Inc. | — | $2.0M |
| 2553 | Venn Therapeutics, LLC | — | — |
| 2554 | Kovina Therapeutics Inc. | — | $2.0M |
| 2555 | CUROVERSE, INC. | — | $2.0M |
| 2556 | NEXILICO, INC. | — | — |
| 2557 | Hennepin Life Sciences | — | $1.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Elliot AndrophyDirector · Executive Officer
- Fritz FrenchDirector · Executive Officer
- Susan MahonyDirector
- William RingoDirector
- Kristin ShermanDirector · Executive Officer
- Teri WilleyDirector
Patents
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsgranted
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsgranted
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsapplication
- Compositions And Methods For Treating Human Papillomavirus Infectionsapplication
- Compositions And Methods For Treating Human Papillomavirus Infectionsgranted
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsgranted
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsgranted
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsapplication
- Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infectionsapplication
- Antiviral Drug Treatment For Human Papillomavirus Infectionsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.